NCT01705795View on ClinicalTrials.gov

Anti-IL-5 Therapy in Bullous Pemphigoid (BP)

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 13, 2013

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Pemphigoid, Bullous
Interventions
DRUG

Mepolizumab (a-IL-5 antibody)

750mg mepolizumab four times over four months

DRUG

Placebo

Nacl four times over four months

Trial Locations (1)

3010

Dep. of Dermatology, Bern University Hospital, Bern

All Listed Sponsors
lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT01705795 - Anti-IL-5 Therapy in Bullous Pemphigoid (BP) | Biotech Hunter | Biotech Hunter